Czech Republic

BMI View: Despite risks to the Czech Pharmaceutical market posed by upcoming healthcare reforms and unfavourable changes to pricing and reimbursement regimes, the market remains one... 2011-03-15

BMI View: Current disputes between pharmaceutical industry associations and the Czech government has created uncertainty for BMI's pharmaceutical expenditure forecast scenario. By extension,... 2011-02-04

BMI View: The Czech Republic is set to introduce major healthcare reforms in 2011 that we forecast to have damaging consequences for the country's pharmaceutical industry. The latest... 2011-01-17

BMI View: The attractiveness of Central and Eastern Europe (CEE) to multinational pharmaceutical companies has increased. The region scored 51.6 out of 100 in BMI's Pharmaceutical &... 2011-01-13

BMI View: Throughout 2009, the Czech Republic's pharmaceutical market demonstrated resilience to the introduction of fixed co-payments for healthcare services and a poor macroeconomic... 2010-11-15

BMI View: The attractiveness of Central and Eastern Europe (CEE) to multinational pharmaceutical companies has declined. The region scored 51.5 out of 100 in BMI's Pharmaceutical &... 2010-10-27

BMI View: The application of an innovative medical device with generic medicines is a commendable approach by the Sanofi-Aventis subsidiary Zentiva. This combination will achieve significant... 2010-10-06

BMI View: Pharmaceutical firms in the Czech Republic need to both diversify and redirect pharmaceutical exports towards countries with improved long-term pharmaceutical growth potential... 2010-09-17

BMI View: The new centre-right coalition's plans for the healthcare sector in the Czech Republic are broadly favourable in terms of financial sustainability and positive implications... 2010-08-10

BMI has introduced greater clarity to its core views for the Pharmaceuticals & Healthcare. Short-term core views concern the period through to the end of the 2011-2013 patent cliff,... 2010-03-15